IRVING, Texas, July 20, 2020 /PRNewswire/ -- Darling
Ingredients Inc. (NYSE: DAR), today announced that its Rousselot
business, the global leader of collagen-based solutions, has
successfully introduced X-Pure® GelMA at Bio Digital 2020. The
first Good Manufacturing Practice (GMP)-ready range of gelatin
methacryloyl (GelMA) biomaterials suitable for preclinical and
clinical applications. X-Pure® GelMA is part of the X-Pure®
portfolio of ultra-pure gelatins and collagens, suitable for use as
biomaterials in 3D bioprinting, tissue engineering, and
regenerative medicine.
![Darling International Inc. (PRNewsfoto/Darling International Inc.) Darling International Inc. (PRNewsfoto/Darling International Inc.)](https://mma.prnewswire.com/media/647660/Darling_Ingredients_Logo.jpg)
In GelMA hydrogels, the most versatile biological environment
for cells, the inherent bioactivity, biodegradability, and cell
compatibility of gelatin are combined with the ability to tailor
photo-crosslinking. This combination holds a huge potential for the
creation of tunable biological environments for the culture of
various eukaryotic cells at body temperature. Uses for this
biomedical technology could be bio-adhesives for patching arteries,
transdermal needles for drug delivery or act as a matrix for bone
regeneration.
X-Pure® GelMA - The first GMP-ready gelatin methacryloyl.
GelMA-oriented patent applications have been growing exponentially
over the last five years, with many of these research concepts now
being translated into the clinic. However, standard GelMA products
often carry high and variable levels of soluble impurities
originating from either the gelatin raw material or the chemical
synthesis process. The presence of these impurities such as
endotoxins, pyrogens and/or methacrylic acid residues are
detrimental for in-body use but can also affect the success of in
vitro applications. X-Pure® GelMA provides an ultra-pure
solution.
"We are pleased that our Rousselot development team has
delivered on this exciting new product for the biomedical
marketplace," said Randall C.
Stuewe, Chairman and Chief Executive Officer of Darling
Ingredients. "Rousselot continues to be a global leader of
collagen-based solutions for food, biomedical and pharmaceutical
sectors."
Rousselot's unique patented two-stage purification process
results in ultra-low levels of pyrogens and residual methacrylic
acid, providing an excellent safety profile to the product.
Further, consistent batch-to-batch quality ensures reliable results
and shorter lead times to the clinic.
"Our X-Pure® products are unique on the market, as they come
with ultra-low levels of endotoxins and fully validated
traceability of raw materials," stated Jos Vervoort, Executive Vice
President of Rousselot. "X-Pure® GelMA is our latest addition to
our biomedical range of ultra-pure gelatins and collagens and our
range will be further extended as we move forward with products
bringing added value to the whole biomedical industry."
Readily available, X-Pure® GelMA can be produced in compliance
with GMP regulatory requirements for quality, raw material
sourcing, and documentation for approval across all major
regulators worldwide, thereby minimizing regulatory risks and
optimizing the pace of product development. The new range covers a
broad choice of molecular weights and modification degrees of
gelatin methacryloyl biomaterials, allowing close customer
collaboration for custom-made solutions.
Contact Darling Ingredients' Rousselot business to speak to an
expert on how X-Pure® GelMA will impact the medical community and
further meet the needs of an aging population at
www.rousselot.com/biomedical.
To watch more on the benefits of X-Pure® GelMA:
https://youtu.be/jBnH4FUffYQ
About Darling
Darling Ingredients Inc. is a global
developer and producer of sustainable natural ingredients from
edible and inedible bio-nutrients, creating a wide range of
ingredients and specialty solutions for customers in the
pharmaceutical, food, pet food, feed, technical, fuel, bioenergy,
and fertilizer industries. With operations on five
continents, the Company collects and transforms all aspects of
animal by-product streams into useable and specialty ingredients,
such as gelatin, edible fats, feed-grade fats, animal proteins and
meals, plasma, pet food ingredients, organic fertilizers, yellow
grease, fuel feedstocks, green energy, natural casings and
hides. The Company also recovers and converts recycled oils
(used cooking oil and animal fats) into valuable feed and fuel
ingredients and collects and processes residual bakery products
into feed ingredients. In addition, the Company provides
environmental services, such as grease trap collection and disposal
services to food service establishments. The Company sells its
products domestically and internationally and operates within three
industry segments: Feed Ingredients, Food Ingredients and Fuel
Ingredients. For additional information, visit the Company's
website at http://www.darlingii.com.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more
information contact:
|
|
|
|
Investors
|
Media
|
Jim
Stark
|
Melissa
Gaither
|
VP, Investor
Relations
|
VP, Global
Communications & Sustainability
|
+1 (972)
281-4823
|
+1 (972)
281-4478
|
James.stark@darlingii.com
|
mgaither@darlingii.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/x-pure-gelma-purest-modified-gelatin-for-translational-medicine-301095651.html
SOURCE Darling Ingredients Inc.